STUDY OBJECTIVES: To assess the treatments received and outcomes of patients with early stage non-small cell lung carcinoma (NSCLC). DESIGN: A retrospective study of patients identified from the institutional tumor registry between 1994 and 1999. SETTING: The Richard L. Roudebush VA Medical Center, Indianapolis, IN. PATIENTS: All patients with stage I and II NSCLC as identified above. INTERVENTIONS: None. MEASUREMENTS AND RESULTS: Of 128 patients identified, 49 patients received no cancer treatment, 36 patients received radiation therapy only, and 43 patients were treated with primary surgery. Median +/- SD survival time following surgery was 46.2 +/- 3.15 months; for no treatment, 14.2 +/- 2.37 months (p = 3.2 x 10(-6)); and radiotherapy alone, 19.9 +/- 5.6 months (p = 0.0005). Of those who received no specific cancer treatment, 14 patients refused treatment and the remainder were not treated for a variety of medical reasons. Cause of death was cancer in 53% of untreated patients and 43% for those receiving radiotherapy. Radiotherapy was administered for postobstructive atelectasis, hemoptysis, increasing tumor size, pain, pleural effusion, and medical inoperability. Radiation dosages had no apparent standard. No significant differences in survival were found for patients receiving radiotherapy with either curative or palliative intent (20.3 months vs 16.0 months, respectively; p = 0.229). CONCLUSIONS: Within the limitations of this retrospective study, it appears that untreated early stage lung cancer has a poor outcome, with > 50% of patients dying of lung cancer. Surgery remains the treatment of choice, but lung cancer screening programs will result in increasing numbers of medically inoperable patients with no clear policies for their management.
STUDY OBJECTIVES: To assess the treatments received and outcomes of patients with early stage non-small cell lung carcinoma (NSCLC). DESIGN: A retrospective study of patients identified from the institutional tumor registry between 1994 and 1999. SETTING: The Richard L. Roudebush VA Medical Center, Indianapolis, IN. PATIENTS: All patients with stage I and II NSCLC as identified above. INTERVENTIONS: None. MEASUREMENTS AND RESULTS: Of 128 patients identified, 49 patients received no cancer treatment, 36 patients received radiation therapy only, and 43 patients were treated with primary surgery. Median +/- SD survival time following surgery was 46.2 +/- 3.15 months; for no treatment, 14.2 +/- 2.37 months (p = 3.2 x 10(-6)); and radiotherapy alone, 19.9 +/- 5.6 months (p = 0.0005). Of those who received no specific cancer treatment, 14 patients refused treatment and the remainder were not treated for a variety of medical reasons. Cause of death was cancer in 53% of untreated patients and 43% for those receiving radiotherapy. Radiotherapy was administered for postobstructive atelectasis, hemoptysis, increasing tumor size, pain, pleural effusion, and medical inoperability. Radiation dosages had no apparent standard. No significant differences in survival were found for patients receiving radiotherapy with either curative or palliative intent (20.3 months vs 16.0 months, respectively; p = 0.229). CONCLUSIONS: Within the limitations of this retrospective study, it appears that untreated early stage lung cancer has a poor outcome, with > 50% of patients dying of lung cancer. Surgery remains the treatment of choice, but lung cancer screening programs will result in increasing numbers of medically inoperable patients with no clear policies for their management.
Authors: Robert Timmerman; Rebecca Paulus; James Galvin; Jeffrey Michalski; William Straube; Jeffrey Bradley; Achilles Fakiris; Andrea Bezjak; Gregory Videtic; David Johnstone; Jack Fowler; Elizabeth Gore; Hak Choy Journal: JAMA Date: 2010-03-17 Impact factor: 56.272
Authors: Pier Luigi Filosso; Alberto Sandri; Alberto Oliaro; Andrea Riccardo Filippi; Maria Carla Cassinis; Umberto Ricardi; Paolo Olivo Lausi; Sofia Asioli; Enrico Ruffini Journal: Lung Cancer (Auckl) Date: 2011-06-08
Authors: Jeffrey A Bogart; Lydia Hodgson; Stephen L Seagren; A William Blackstock; Xiaofei Wang; Robert Lenox; Andrew T Turrisi; John Reilly; Ajeet Gajra; Everett E Vokes; Mark R Green Journal: J Clin Oncol Date: 2009-11-23 Impact factor: 44.544